VBI Vaccines Inc.

VBI Vaccines — Immuno-Oncology Summit 2017

25 slides from VBI Vaccines's conference presentation, Aug 30, 2017

  1. Slide 1: Harnessing the Immunogenicity of Foreign Viral CMV Antigens to Target Solid Tumors

    (VBI VACCINES Coma HARNESSING THE IMMUNOGENICITY OP FOREIGN VIRAL CMV ANTIGENSTO TARGET SOLID TUMORS NASDAQ: VBIV IMMUNO-ONCOLOGY SUMMIT TSX: VBV AUGUST 30 2017

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Information

    Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collective

  3. Slide 3: Agenda

    li Agenda 2 3 Intro & eVLP Platform Overview Significance of CMV as a Tumor Target VBI-1901 IND-Enabling Data Summary

  4. Slide 4: Convergence of Vaccinology & Immuno-oncology — Cancer Vaccines 3.0

    Convergence of Vaccinology & Immuno-oncology — Cancer Vaccines 3.0 Live Viral Themes of Convergence: laccines ‘Reductionist’ Peptide Subunit vaccines * Antigen selection * Immunogenicity RecProtein +/- Adjuvants @ VLPs * Self vs Foreign Viral Vector mRNA & DNA 2 (?) « Antigen delivery (?) * Recognit

  5. Slide 5: eVLP Platform: enveloped virus-like particles that leverage innate immune signaling

    eVLP Platform: enveloped virus-like particles that leverage innate immune signaling to stimulate anti-tumor immunity eVLP Overview Customizable constructs that mimic enveloped viruses as they occur in nature: * Key structural components eVLP Features v Natively stimulate adaptive and innate immunity

  6. Slide 6: VBI-1901: Rationally designed therapeutic CMV vaccine for solid tumors

    VBI-1901: Rationally designed therapeutic CMV vaccine for solid tumors VBI-1901: Therapeutic CMV Schematic Virus-like Structure Stimulates Innate Immunity & Promotes Uptake by Antigen Presenting Cells (APCs) Antibody Targets gB ‘Foreign’ Tumor Associated Viral Antigens (TAVA) are naturally immunogen

  7. Slide 7: Significance of CMV as a Tumor Target

    Rl Vie! Significance of CMV as a Tumor “oy Target faa evbiz Soe NASDAQ: VBIV | TSX: VBV 7

  8. Slide 8: Foreign viral antigens, like CMV, enable immune targeting in cold tumors

    Foreign viral antigens, like CMV, enable immune targeting in “cold” tumors where checkpoints inhibitors have been less successful voi Occasional Neoantigen Formation Frequent Neoantigen Formation Typically “Colder” Tumors Typically “Hotter” Tumors Formation of neoantigens 1000 p= j| Frequently 8 Reg

  9. Slide 9: Broad evidence supports CMV as a cancer immunotherapeutic target

    Broad evidence supports CMV as a cancer immunotherapeutic target Body of Evidence Suggests a CMV Vaccine That Can Stimulate DCs & Restimulate CMV-Specific T-cells Has Potential for Clinical Efficacy * Prins RM (2008) ~ Autologous, GBM tumor lysate DC vaccine © Single imzn. increased CMV pp65-specifi

  10. Slide 10: Duke-led study demonstrates CMV dendritic cell vaccines can increase pp65 immunity

    Duke-led study demonstrates that CMV dendritic cell vaccines can increase pp65 immunity (Batich et al, 2017) Trial Design Clinical Results + 11 patients received at least 3 doses of pp65- * >3 times longer progression-free survival dentritic cells after dose-intensified temozolomide * >2 times longe

  11. Slide 11: VBI-1901 IND-Enabling Data

    VBI-1901 IND-Enabling Data ns, evbiz Xena NASDAQ; VBIV | TSX: VBV 11

  12. Slide 12: VBI-1901: Elicits Balanced Cellular & Humoral Immunity

    CD3*CD4*IFNy* (%) voi VBI-1901: Elicits Balanced Cellular & Humoral Immunity Tumor Clearance by CTLs is Known to be Enhanced by CD4 & Antibody Responses pp65-specific Th1 cells gB-specific CTLs gB-specific antibody response 2. - ' 3 = 6 3 3 & g 2 = = a 3 oO 2 = a < Oo Naive mice (n= 4 or 8/group) we

  13. Slide 13: VBI-1901: Potential Off-the-Shelf Dendritic Cell Vaccine

    VBI-1901: Potential “Off-the-Shelf” Dendritic Cell Vaccine VBI-1901 Recruits (CCL3) and Activates (IL-8) Dendritic Cells CCL3 IL-8 _ 8 = 250 = = D6 je ee = = er = CCL3: gB/pp65 eVLPs ce 100 = gBipp65 eVLPs 3 -® CCL3: Human serum albumin £199 == Human serum albumin 2 2 § 2 8 é 2 0 50 100 150 200 0 20

  14. Slide 14: VBI-1901: Stimulates Innate Immunity

    VBI-1901: Stimulates Innate Immunity eVLP particles stimulate IL-8 (independent of antigen) Inclusion of gB/pp65 antigens stimulates additional pro-inflammatory cytokines IL8 Monocytes Note: Human monocytes ‘0000 = were purified by negative som Mm Bipocs selection to >90% purity z eas and stimulated

  15. Slide 15: VBI-1901: Stimulates Innate Immunity (CMV-gB driven)

    OOOO eee VBI-1901: Stimulates Innate Immunity Antigen specific upregulation of pro-inflammatory cytokines is driven by CMV-gB voi 46% Gl gB/pp65 eVLPs HB gB/pp65 eVLPs + anti-gB mAb Cytokine Secretion (pg/ml) 3 >» so IN s NY, vy ; & s S i; ~ gB Monoclonal Can Neutralize Stimulation of Innate Cytokin

  16. Slide 16: VBI-1901: Re-stimulates CMV-specific Immunity in Human Ex Vivo Samples

    VBI-1901: Re-stimulates CMV-specific Immunity in Human Ex Vivo Samples Restimulation of CD4+ & CD8+ T-cells in Ex Stimulation of CCL3 in CMV+ Tumors — Vivo Human Samples Correlated to >O.S. by Mitchell et al (2015) = cD4*IFN-y* CD8*IFN-;* = 9 2 £ Oo pou 5 = 2 2 2 < ° g Z 1. ° s - ° 3 iof como 8 3 fe

  17. Slide 17: VBI-1901: Boosts CMV pp65-specific IFN-y T cell Responses in Macaques

    VBI-1901: Boosts CMV pp65-specific IFN-y T cell Responses in Macaques Batich et al (2017) Observed CD8 T-cell Immunity after 3-doses & Improved Overall Survival VBI-1901 Restimulates CD8 Immunity in CMV+ Monkeys — Basis for Clinical Evaluation VBI-1901 + GM-CSF (Two Doses) = 2 nN aoasg w <P Pre-vacc

  18. Slide 18: VBI-1901: Overview of CMC Process

    VBI-1901: Overview of CMC Process Process optimized to preserve particle integrity & meet FDA standards Cla (Depth filtration) j ow Assay Description Test Result Concentrate particles (Tangential flow filtra Residual host cell DNA 1.4 ng/ug pp65 (quantitative PCR) Inactivate residual host DNA and ad

  19. Slide 19: VBI-1901: IND Enabling Tox & Safety

    TTT VBI-1901: IND Enabling Tox & Safety * — Standard Toxicology v No adverse events seen with VBI-1901 v eVLPs already safely evaluated in Ph! * Biodistribution Study Y Vaccine observed at injection site for up to 14 days (depot effect) Y¥ No accumulation in major organs * — Off-target Toxicology Y

  20. Slide 20: VBI's prophylactic CMV vaccine achieved dose-dependent immune responses

    VBI’s prophylactic CMV vaccine (similar design to 1901) achieved dose-dependent immune responses against CMV (interim Ph1 data) After only two vaccinations @ 2.0ug, 100% of subjects seroconvert - Exceptionally immunogenic vaccine platform * Seroconversion* in 100% of subjects + eVLPs highly immunoge

  21. Slide 21: Opportunity & Clinical Development Plan

    Rl vbi Opportunity & Clinical “oy Development Plan a evbiz Soe NASDAQ: VBIV | TSX: VBV 2

  22. Slide 22: Initial Clinical Development of VBI-1901 Will Focus on GBM

    voi Initial Clinical Development of VBI-1901 Will Focus on GBM - A Profound Unmet Medical Need GBM is the most aggressive form of brain cancer No standard of care options after initial surgery/radiation/chemotherapy Invasive primary tumor margins and secondary tumors are interspersed among healthy g

  23. Slide 23: VBI-1901 Comparison to Recent Clinical IO Advances in GBM

    VBI-1901 Comparison to Recent Clinical 1O Advances in GBM Breadth of Reactivity may be an Important Parameter for Efficacy Company/Inst. Key Finding Take-Away Novartis - CTLO19 BMS - Checkmate 143 Merck ~ Keynote 028 Duke - Batich (et al) VBI Vaccines voi EGFRvIll specific CAR-T PD1, PDL1 pp65 loade

  24. Slide 24: VBI-1901: Potential Off-the-Shelf Vaccine for CMV+ Solid Tumors

    VBI-1901: Potential ‘Off-the-Shelf’ Vaccine for CMV+ Solid Tumors Leverages inherent immunogenicity of CMV to target CMV-positive Off-The-Shelf Design SUutelgs Easily manufactured and scalable CMV is expressed in over 90% of Glioblastoma (GBM), Breast, Colorectal & other solid tumors High unmet need

  25. Slide 25: =VOI

    wm, SS = o => =VOI G Zam VBI Vaccines, Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 \’ Uf yii\ [email protected] NASDAQ; VBIV | TSX: VBV

VBI Vaccines — Immuno-Oncology Summit 2017 on 6ix